Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

Johnson & Johnson announces TREMFYA® (guselkumab) is the first and only IL-23 ...

25 September 2026 · By · Wire by Fusion42

Published

25 September 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at jnj.com →

◆ Verified

Fusion42 · 25 September 2026 · Fusion42 review

Johnson & Johnson's TREMFYA® (guselkumab) demonstrated significant improvement in spinal pain, stiffness, and inflammation in a Phase 4 study (STAR) for patients with axial psoriatic arthritis, marking it as the first IL-23 inhibitor proven to halt further joint damage in this population.

This Wire brief sits within Fusion42's coverage of Biotech.

◆ ◆ The Wire takeaway

You have a new treatment benchmark with TREMFYA approved to stop joint damage in axial psoriatic arthritis. This opens urgent opportunities to pivot or start targeting patients with axial symptoms who previously lacked dedicated options.

◆ Coverage

1 source · 25 Sep 2026

◆ Related on Wire

◆ Topics

Biotechpsoriatic-arthritisclinical-trialsIL-23-inhibitorbiologic-therapyTREMFYA